Media.Player

POSH Inhibitor Peptide Amphiphile Micelles as a Novel Cancer Therapeutic Modality

详细技术说明

None

*Abstract

University of MissouriOffice of Technology Management & Industry RelationsNon-Confidential Abstract of InventionUM Disclosure No. 16UMC041Peptide Amphiphiles as a Novel Cancer Therapeutic ModalityTECHNOLOGY DESCRIPTION:University of Missouri researchers have developed a group of novel peptides that target a common set of biological pathways important in T cell function, activation of innate inflammation, ischemic reperfusion injury, HIV release and oncogenesis. The targeted pathways converge on (or are regulated by) POSH, a specific scaffold molecule, that functions to assemble components of signaling pathways that regulate basic cell biological processes of division, survival, death, development and differentiation. The deregulation of these pathways is implicated in cancer, autoimmunity, inflammation, as well as the function and development of T cells and neurons. Therefore, the application of these compounds in a therapeutic is likely to impact numerous therapeutic areas.The novel group of peptides can be delivered to cellular sub-populations by synthesizing micelle nanostructures with aptamers as targeting moieties. These delivery modality allows the novel group of compounds overcome the problem of susceptibility to enzymatic degradation and limited internalization capacity. The research has shown promising in vitro results, and due to the low toxicity of the novel peptides, the researchers are enthusiastic about the upcoming animal trials, which will position the technology for clinical trials.POTENTIAL AREAS OF APPLICATIONS:• Leukemia Treatment• Colon, Breast, and Liver Cancer TreatmentMAIN ADVANTAGES OF INVENTION:• Low to no toxicity• In vitro testing led to death of 4 out of 4 T cell lymphomas and 4 out of 4 B cell lymphomas and 17 out of 17 T and B cell leukemias without impacting homeostasis of normal T and B cells• Innovative efficient method of peptide amphiphile formation• Delivery of specially formulated peptide to location of interestINVENTOR(S):• Bret Ulery • Mark Daniels • Josiah Smith • Erin Newcomer • Leah CardwellCONTACT INFO: Office of Technology Management & Industry Relations Brett Maland, J.D. MBA Senior Licensing & Business Development Associate Email: malandb@missouri.edu Phone: 573-882-1046

*Principal Investigation

Name: Bret Ulery, Asst Professor

Department:

Name: Mark Daniels, Assistant Professor

Department:

Name: Josiah Smith, Grad Student

Department:

Name: Erin Newcomer, Undergrad Researcher

Department:

Name: Leah Cardwell, Graduate Student, MMI

Department:

其他

国家/地区

美国